Bookmark

Add to MyYahoo RSS

Isis Pharmaceuticals News

News on Isis Pharmaceuticals (Ticker: ISIS) continually updated from thousands of sources around the net.

Sunday Jul 20 | The Motley Fool

ISIS Pharmaceuticals, Inc. is The Best Stock Today

The Motley Fool's Better Stock Today tournament has declared a winner! Among the 32 companies pitted against each other our reader's voices your voice were heard loud and clear : Isis Pharmaceuticals is the best stock today.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Jul 16, 2014

Applied Clinical Trials

Isis Pharmaceuticals Earns $1 Million from GSK for Advancing ISIS-TTR Rx

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Genetics, Marketing

Fri Jul 11, 2014

AmericanBankingNews.com

Isis Pharmaceuticals Inc 1,800 Shares of Regulus Therapeutics Stock

Regulus Therapeutics Director Isis Pharmaceuticals Inc 1,800 shares of the company's stock in a transaction that occurred on Wednesday, July 9th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Wed Jul 02, 2014

BioSpace

Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For...

"Our collaboration with GSK has been very productive resulting in three novel antisense drugs in our pipeline.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Hepatitis, Health, Liver Cancer

Contract Pharma Breaking News

Isis Earns GSK Milestone

Isis Pharmaceuticals, Inc. has earned a $1 million payment from GlaxoSmithKline for the advancement of its development program for antisense drugs to treat hepatitis B virus .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Hepatitis, Health

Thu Jun 26, 2014

Pharmaceutical Online

Isis Receives $1M Milestone From GSK For FAP Drug

Isis Pharmaceuticals announced this week that it has earned a $1 million milestone payment from GlaxoSmithKline after advancing its investigational drug ISIS-TTR Rx in a Phase II/III study in patients with familial amyloid polyneuropathy .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Genetics

Wed Jun 25, 2014

AmericanBankingNews.com

Insider Selling: ISIS Pharmaceuticals SVP Sells 11,200 Shares of Stock

ISIS Pharmaceuticals SVP C Frank Bennett sold 11,200 shares of the company's stock in a transaction dated Monday, June 23rd.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Jun 24, 2014

BioSpace

Isis Pharmaceuticals, Inc. Earns $1 Million From GlaxoSmithKline For Advancing ISIS-TTR Rx

ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, GlaxoSmithKline, Genetics, Marketing

Mon Jun 23, 2014

The Motley Fool

Better Buy: Isis Pharmaceuticals vs. Arrowhead Research

Earlier this year, clinical-stage biotechs fell in dramatic fashion, as investors turned toward bigger health-care names generating revenue from approved products.

Comment?

Related Topix: Biotech, Arrowhead Research, Medicine, Healthcare Industry, Healthcare Law, Law, Genetics

•••
•••
•••
•••
•••

Ashburn Jobs

•••
•••
•••
•••